The current 2021 European Society of Cardiology (ESC) guidelines for the treatment of HF recommend the parallel, early introduction and up‐titration of the four pillars of HFrEF, including renin‐angiotensin system inhibitors (RASi; angiotensin‐converting enzyme inhibitors [ACEI], angiotensin receptor‐neprilysin inhibitor [ARNI], angiotensin receptor blockers [ARB] in the case of ACEI and ARNI intolerance), beta‐blockers (βB), mineralocorticoid receptor antagonists (MRA), and sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin/empagliflozin.1 Here, ACE is linked to hydrops fetalis.